The present disclosure relates generally to various forms and compositions useful as beta adrenergic agonists and uses of the same in the treatment of diseases associated with an adrenergic receptor. In one aspect, the disclosure provides a crystalline solid form of Compound 1: selected from Form A and Form B and salt forms thereof.

##STR00001##

Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

A compound, a photoresist composition including the compound, and a method of manufacturing an integrated circuit device by using the photoresist composition, the compound being represented by Chemical Formula 1:

##STR00001##

The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

The present invention describes an oligomer for use as a UV stabiliser. In particular, the oligomer is suitable for use as a UV stabiliser in a polymer matrix. The present invention also describes a method of forming said oligomer. The method of forming said oligomer comprises a polymerising step, wherein the polymerising step comprises forming a C—C bond on the hydroxyphenyl ring of a monomer. In preferred embodiments, the oligomer is formed from polymerizing bio-derived monomer such as curcumin, its hydrogenated analogue, and an aldol condensation product of cyclic ketone and vanillin.

Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a cell proliferative disorder such as a cancer using a compound of formula I

##STR00001##

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R and R.sub.1, different, are selected from the group consisting of

##STR00002## wherein when one of R and R.sub.1 is a —H, the other of R and R.sub.1 is a cyclopentyl moiety, R.sub.2 is a benzyl substituted with 1-5 halogens, preferably —Cl or —F, and R.sub.3 is selected from the group consisting of —H or —OH.

The present invention relates to novel compounds and their use as fragrance materials.

Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.